Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Restenosis of the superficial femoral artery (SFA) following endovascular treatment remains a significant clinical challenge in peripheral artery disease (PAD). This study evaluates the prognostic value of the Aggregate Index of Systemic Inflammation (AISI) as a biomarker for predicting restenosis risk in SFA lesions.
Methods: In a retrospective cohort study, 632 patients undergoing endovascular interventions for symptomatic PAD were analyzed. AISI was calculated as: (neutrophils × platelets × monocytes)/lymphocytes. Patients were divided into 2 groups as those who developed restenosis and those who did not develop restenosis. Multivariate logistic regression and Cox proportional hazards models were used to identify independent predictors of restenosis.
Results: Among 632 patients, 142 developed restenosis. The median AISI was significantly higher in the restenosis group compared to the nonrestenosis group (909.28 vs. 516.59, P < 0.001). Patients with high AISI demonstrated a 2.13-fold increased risk of restenosis (hazard ratio: 2.133, 95% confidence interval: 1.508-3.017, P < 0.001) and a shorter time to restenosis (median: 6 months vs. 12 months). Smoking, presence of prior intervention, intervention types, and stent-graft use were also associated with an elevated risk of restenosis. Receiver operating characteristic analysis identified an AISI cutoff value of 489.64 (sensitivity: 57%, specificity: 56%, area under the curve: 0.623).
Conclusion: AISI is a promising inflammatory biomarker for predicting the risk of restenosis in PAD patients undergoing endovascular treatment of the SFA. Incorporating AISI into clinical practice could enhance risk stratification and guide personalized management strategies. Prospective studies are needed to confirm these findings and further investigate the mechanistic role of systemic inflammation in restenosis development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.avsg.2025.06.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
Novel Strategies to Conquer Residual Adiposity Risk in Cardiovascular Disease.
Curr Atheroscler Rep
September 2025
Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Purpose Of Review: Despite major advances in the treatment and prevention of atherosclerotic cardiovascular disease (ASCVD), a substantial burden of residual risk remains Obesity has been redefined as a primary and independent drivers of cardiovascular morbidity and mortality warranting focused attention.
Recent Findings: Obesity is now recognized as a chronic disease and a central contributor to residual cardiovascular risk through mechanisms including systemic inflammation, insulin resistance, dyslipidemia, and endothelial dysfunction. This review addresses the limitations of conventional obesity management and highlights emerging pharmacological therapies targeting the underlying adiposopathy.
Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms-a comprehensive review.
Mol Cell Biochem
September 2025
Peking University Third Hospital, Beijing, China.
Cardiovascular-Kidney-Metabolic (CKM) syndrome, a newly defined systemic disorder, is characterized by the pathological interplay among diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). Recent studies have identified chronic inflammation not only as a central mediator in the pathological progression of CKM syndrome but also as a pivotal molecular hub that drives coordinated damage across multiple organ systems. Mechanistic investigations have revealed that aberrant activation of signaling pathways such as NF-κB, Wnt, PI3K-AKT, JAK-STAT, and PPAR constitutes a complex inflammatory regulatory network.
View Article and Find Full Text PDFsubsp. B-53 Alleviated Abnormalities of Glycolipid Metabolism and Oxidative Stress in T2DM Mice Through Regulating Gut Microbiota and GLP-1 Secretion.
J Agric Food Chem
September 2025
Center of Drug Safety Evaluation, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Creating effective treatments for type 2 diabetes mellitus (T2DM) remains a critical global health challenge. This study investigates the antidiabetic mechanisms of subsp. B-53 ( B-53) in T2DM mice.
View Article and Find Full Text PDFMyopathology and Immune Profile of Granulomatous Myositis in Sarcoid Myopathy.
Neuropathol Appl Neurobiol
October 2025
Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Aims: Sarcoid myopathy (SaM) is characterised by granulomatous myositis (GM) and can overlap with inclusion body myositis (IBM), a late-onset chronic idiopathic inflammatory myopathy with a still enigmatic pathogenesis. As GM can occur in different clinical contexts, we aimed to examine the histomorphologic features and gene expression profiles in cases of definite SaM that may inform diagnostic and therapeutic considerations.
Methods: We performed a multidimensional characterisation of muscle biopsy specimens from patients with 'pure SaM' (n=17), SaM with concomitant IBM (SaM-IBM) (n=2), including histopathologic and ultrastructural analysis in addition to quantitative real-time polymerase chain reaction.